Loading

SCIENCE

  • by Paul Armentano, NORML Deputy Director October 30, 2017

    medical_mj_shelfMembers of the US House Committee on Veteran’s Affairs are demanding the Department of Veterans Affairs facilitate protocols to assess the efficacy of medical cannabis in veterans suffering from chronic pain and post-traumatic stress.

    Minnesota Democrat Tim Walz, along with nine other Democrat members of the Committee, authored an October 26, 2017 letter to VA Secretary David Shulkin stating: “[The] VA is uniquely situated to pursue research on the impact of medical marijuana on veterans suffering from chronic pain and PTSD given its access to world class researchers, the population it serves, and its history of overseeing and producing research resulting in cutting-edge medical treatments. … VA’s pursuit of research into the impact of medical marijuana on the treatment of veterans diagnosed with PTSD who are also experiencing chronic pain is integral to the advancement of health care for veterans and the nation. We ask VA to respond … with a commitment to the development of VHA-led research into this issue.”

    In September, representatives from The American Legion addressed a separate letter to VA Secretary Shulkin encouraging the VA assist in an ongoing, FDA-approved clinical trial assessing the safety and efficacy of various strains of cannabis in veterans with PTSD. To date, the VA has refused to assist in patient recruitment for the trial. The VA has yet to publicly respond to the Legion’s letter.

    Survey data finds that military veterans report using cannabis therapeutically at rates far higher than the do those in the general population, and that many are already using it as an alternative to conventional medications in the treatment of pain and post-traumatic stress.

  • by NORML October 23, 2017

    HumboldtOne of NORML’s primary missions is to move public opinion sufficiently to legalize the responsible use of marijuana by adults. One of the ways we successfully achieve this goal is by debunking marijuana myths and half-truths via the publication of timely op-eds in online and print media. Since the mainstream media seldom casts a critical eye toward many of the more over-the-top claims about cannabis, we take it upon ourselves to set the record straight.

    The majority of NORML’s rebuttals are penned by Deputy Director Paul Armentano. In the past few weeks, he has published numerous op-eds rebuking a litany of popular, but altogether specious claims about the cannabis plant – including the contentions that cannabis consumption is linked to poor health outcomes, problems with regulations, and the effects of opioid abuse, hospitalizations, and fatalities in the states that have robust medical marijuana programs.

    Below are links to a sampling of his recent columns:

    Trump’s opioid agency fails to cite marijuana’s benefits, despite mounting evidence
    The Hill, October 23, 2017

    This is how legal cannabis is improving public health
    National Memo, October 22, 2017

    RMHIDTA’s marijuana reports are nothing but propaganda
    Denver Westword, October 21, 2017

    Marijuana is now a driving engine of the American economy
    Alternet, September 28, 2017

    When will our govt stop ignoring that marijuana is a major regulation success story
    Alternet, September 19, 2017

    Blowing up the big marijuana IQ myth — The science points to zero effect on your smarts
    The National Memo, August 7, 2017

    For a broader sampling of NORML-centric columns and media hits, please visit NORML’s ‘In the Media’ archive here.

    If you see the importance of NORML’s educational and media outreach efforts, please feel free to show your support by making a contribution here.

  • by Paul Armentano, NORML Deputy Director October 20, 2017

    Medical marijuanaAdults with a history of cannabis use are less likely to suffer from non-alcoholic fatty liver disease (NAFLD) than are those who have not used the substance, according to data published online in the journal PLoS One. Non-alcoholic fatty liver disease is the most prevalent form of liver disease, affecting an estimated 80 to 100 million people in the United States.

    An international team of researchers from Stanford University in California and the Seoul National University College of Medicine in South Korea evaluated the association between marijuana and NAFLD in a nationally representative sample of over 22,000 adults. Researchers reported that cannabis use independently predicted a lower risk of suspected NAFLD in a dose-dependent manner.

    “Active marijuana use provided a protective effect against NAFLD independent of known metabolic risk factors,” authors determined. “[W]e conclude that current marijuana use may favorably impact the pathogenesis of NAFLD in US adults.”

    The findings are similar to those of a prior study published in the same journal in May. In that study, authors reported that frequent consumers of cannabis were 52 percent less likely to be diagnosed with NAFLD as compared to non-users, while occasional consumers were 15 percent less likely to suffer from the disease.

    Separate data published online earlier this month in the Journal of Viral Hepatitis also concluded that daily cannabis use is independently associated with a reduced prevalence of fatty liver disease in patients co-infected with HIV and hepatitis C.

    Full text of the study, “Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States,” appears online here.

  • by Paul Armentano, NORML Deputy Director October 13, 2017

    Legalize marijuanaRetail cannabis distribution in Colorado is associated with a reduction in opioid-related mortality, according to data published online ahead of print in The American Journal of Public Health.

    A team of investigators from the University of North Texas School of Public Health, the University of Florida, and Emory University compared changed in the prevalence of monthly opioid-related deaths before and after Colorado retailers began selling cannabis to adults.

    They reported: “Colorado’s legalization of recreational cannabis sales and use resulted in a 0.7 deaths per month reduction in opioid-related deaths. This reduction represents a reversal of the upward trend in opioid-related deaths in Colorado.”

    Authors concluded, “Legalization of cannabis in Colorado was associated with short-term reductions in opioid-related deaths.”

    Their data is consistent with prior studies finding that cannabis access is associated with reductions in prescription drug spending, opioid-related hospitalizations, and opioid-related fatalities.

    An abstract of the study, “Recreational cannabis legalization and opioid-related deaths in Colorado, 2000-2015,” appears online here.

  • by Justin Strekal, NORML Political Director October 12, 2017
    Congressman Earl Blumenauer (D-OR) speaking a NORML Conference

    Congressman Earl Blumenauer (D-OR) speaking at a NORML Conference

    On Wednesday, October 11th, Congressional Cannabis Caucus Co-Chair Earl Blumenauer (D-OR) testified before the House Energy & Commerce Subcommittee on Health on how to deal with the opioid crisis in America.

    In his testimony, the Congressman makes the case for medical cannabis as a safer alternative to highly addictive opioids, especially for our veterans—as well as the need to remove barriers to medical cannabis research.

    It is well documented that medical marijuana access is associated with reduced rates of opioid use and abuse, opioid-related hospitalizations, opioid-related traffic fatalities, and opioid-related overdose deaths.

    Watch the video below and click here to send a message to your elected officials in support of the CARERS Act of 2017 in support of medical marijuana and click here to send a message to the Office of National Drug Control Policy’s Opioid Commission to urge them to include medical marijuana as part of the national strategy to combat the opioid crisis.

Page 3 of 8812345...102030...Last »